CEO, One Codex

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

NGS is a powerful method for characterizing complex microbial mixtures, but both short-read 16S and WGS methods have their shortcomings. While short-read 16S data is inexpensive, it only enables family- or genus-level identification, is not comparable across different variable regions, and provides poor relative abundance estimation. WGS, meanwhile, offers more accurate relative abundance estimation and greater specificity, but at increased cost and complexity.

Another approach, LoopSeq synthetic long-read sequencing technology from Loop Genomics, offers an intermediate solution by providing species-level identification and significantly improved relative abundance estimation over short-read 16S data. LoopSeq uses unique molecular identifiers to generate synthetic long reads on short-read Illumina sequencing instruments. 

In this webinar, Nick Greenfield of One Codex will discuss a comparison study of short-read 16S, WGS, and LoopSeq data for four samples – two known composition-positive controls, including a 20-organism bacterial mixture from ATCC, and two complex microbiome samples.

He will share details from this comparison as well as demonstrate how to analyze these datasets on the One Codex software platform.

Sponsored by
1:00 pm2019
Sponsored by

Leveraging Single-Cell Genomics to Identify Drivers of Enhanced Immunity


Pfizer-Laubach Career Development Assistant Professor, Massachusetts Institute of Technology

This webinar highlights the use of single-cell genomics to identify distinct cell types and states associated with enhanced immunity.

Immune homeostasis requires constant regulation in order to maintain the balance between a diverse and dynamic set of cell types under normal physiological conditions. Within immune tissues, distinct cellular subsets must work together to defend against pathogenic threats, maintain tolerance, and establish memory to restore homeostasis. While surveying multiple healthy individuals enables the exploration of potential ensemble immune solutions, comparing this data against outliers of health and disease can reveal deviations that underscore diagnostic, therapeutic, and prophylactic features of enhanced function or dysfunction.

In this webinar, Alex K. Shalek of the Massachusetts Institute of Technology (MIT) will discuss his work using single-cell genomic approaches — in particular, single-cell RNA-seq — to explore the functional diversity among immune cells within and across individuals. This project aims to uncover distinct cell types and states associated with improved immunity from the molecular level.

Dr. Shalek will also expand on the emerging experimental and computational strategies for altering ensemble cellular responses through targeted intra- or extracellular induction of preferred cell types and states.

Sponsored by
12:00 pm2019
Sponsored by
Oxford Nanopore Technologies

Transcriptome of an Agricultural Pest Delineated by Oxford Nanopore RNA-Seq


PhD Candidate, Department of Human Genetics
McGill University, Canada

This webinar will describe a project that applied Oxford Nanopore long-read RNA-seq to explore the transcriptional landscape of a damaging agricultural pest.

Anthony Bayega of McGill University will discuss the study, which looked at the transcriptional dynamics that occur during early embryo development of the olive fruit fly (Bactrocera oleae), a key pest of cultivated olive trees that costs the olive fruits industry an estimated $200 million annually.

Anthony and colleagues combined absolute gene quantification using internal RNA spikes, full-length cDNA sequencing using Oxford Nanopore long-read RNA-seq, and high-resolution timescale experimentation for the study. They generated a de novo transcriptome assembly and identified 3,553 novel genes and a total of 79,810 transcripts.

Dr. Bayega will discuss how he and his team also refined gene models for key sex-determining genes, which might provide insights into biological control of this fly.

Sponsored by
11:00 am2019
Sponsored by
Pillar Biosciences

Rapid Testing of Solid Tumor Samples Using a Single-Vial NGS Assay


Professor of Pathology,
University of Melbourne

This webinar will demonstrate how clinical laboratories can develop their own customized targeted next-generation sequencing (NGS)-based solid tumor panels. 

Clinical labs that offer NGS-based tumor tests with different ranges of genes or mutations need to develop and validate customized assays that are accurate, sensitive, robust, affordable, easy to use, and free from cross-sample contamination. 

Customization, however, can present significant obstacles for labs that lack the experience or financial resources required to design, develop, and validate the assay and interpret novel variants. 

In this webinar, Dr. Paul Waring, Professor of Pathology at the University of Melbourne, will discuss how clinical labs can overcome these challenges. The webinar will provide details of Pillar Biosciences’ SLIMamp chemistry, ONCOReveal custom panel design, and Pillar Variant Analysis Toolkit, which provide clinical laboratories with the means to offer their own customized, affordable, single-tube tests suitable for detecting clinically relevant mutations in formalin-fixed tissue or blood samples with a sensitivity of at least 1%. 

Key topics include:

  • Applications of SLIMamp, a single-vial NGS chemistry to rapidly profile tumor samples
  • Robust, sensitive mutation detection from samples with limited tumor input and liquid biopsies
  • Bioinformatic workflows using the Pillar Variant Analysis Toolkit for rapid mutation identification
  • Customization of the ONCOReveal assay to support clinical trials and identify emerging biomarkers

Due to our speaker being located in a different time zone, this webinar will be pre-recorded. All webinar registrants have the opportunity to submit questions on the registration page and/or you can email them in after the webinar is released on February 19th.

Sponsored by

COO, Gradalis

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations. 

Precision medicine and new classes of immunotherapy treatments, including cell and gene therapies, require a new category of "companion informatics" that automate and synchronize complex manufacturing, quality management, and treatment processes. L7’s Enterprise Science Platform (ESP) is a scientific information management solution that connects people, processes, lab instrumentation, and bioprocess equipment to simplify and optimize biologics research, manufacturing, and treatment. 

This case study showcases L7's ESP’s implementation at Gradalis, where hand-written batch records with manual calculations and ad hoc oversight were initially used for production, analysis, and reporting. 

The webinar will demonstrate ESP's capabilities, including end-to-end visibility, control, compliance, quality management, and automation of an organization’s workflow. ESP interfaces with common lab instruments, bioprocess equipment, and software systems, bringing inventory management, product testing, environmental monitoring, and other quality systems into a single platform. 

Sponsored by
1:00 pm2019
Sponsored by
Advanced Cell Diagnostics

A Cellular and Molecular Phenotyping Pipeline for Target Characterization in FFPE Biobank Samples


Associate Professor in the Department of Medicine, McMaster University 

Masters Candidate, McMaster University

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease. 

Dr. Kjetil Ask will discuss how the clinically relevant tissues were obtained, clinically categorized and deidentified. He will provide his perspective on the requirement of cross-disciplinary expertise and the associated technological platform required for the identification and quantification of cellular and molecular targets in fibrotic lung disease. Dr. Ask will also discuss the potential application of this platform to pre-clinical models of lung disease. 

Megan Vierhout will present her research on the role of alternatively activated macrophages and endoplasmic reticulum stress in fibrotic lung disease. She will show specific examples of automated immunohistochemistry and associated in situ hybridization technology using ACD RNAScope and BaseScope assays to demonstrate molecular phenotyping and target identification. 

Sponsored by
11:00 am2019
Sponsored by
Horizon Discovery

Developing and Validating a Microsatellite Instability Assay for Colorectal Cancer


Senior Scientist, Biocartis

This webinar will discuss development and validation of an assay for detection of microsatellite instability (MSI) based on a novel set of biomarkers.

Detection of MSI is currently recommended for all patients with colorectal cancer (CRC), but MSI is present in several other tumor types such as ovarian and gastric cancer. Current clinical reference methods are immunohistochemical staining of mismatch repair proteins and/or PCR analysis of frequently mutated short tandem repeat regions of DNA, but these approaches are complex and time-consuming.

In this webinar, Bram De Craene of Biocartis will discuss the development and performance of the company's Idylla MSI Assay and will compare the technology with established methods.

The Idylla MSI Assay is available for research use only. Not for use in diagnostic procedures.

Sponsored by

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.